Results 81 to 90 of about 38,450 (306)

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

open access: yes, 2018
Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H   +5 more
core  

Bispecific monoclonal antibodies

open access: yes, 2023
Bispecifična monoklonska protitelesa (bsMAb) so beljakovine, ki se lahko vežejo na dve različni mesti za vezavo antigenov v eni molekuli. S hkratnim prepoznavanjem dveh različnih tarč lahko bispecifična protitelesa zavirajo dve signalni poti, tako da so ...
Matov, Matea
core  

Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies

open access: yesBiopharmaceutics &Drug Disposition, EarlyView.
This study identified new optimal allometric scaling exponents for human PK prediction of monoclonal antibodies with linear PKs from marmoset PK data. In addition, immunogenicity in common marmosets was evaluated following the repeated dose of golimumab and ustekinumab, minimal anti‐drug antibodies were detected.
Ayaka Tajiri   +6 more
wiley   +1 more source

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience

open access: yesActa Haematologica Oncologica Turcica
Aim: This study aimed to assess the real-world performance of elranatamab in terms of its effectiveness, safety, and tolerability among patients diagnosed with triple-class refractory-multiple myeloma (TCR-MM) who have undergone extensive prior treatment.
Ant Uzay
doaj   +1 more source

Homogeneous Bispecifics by Disulfide Bridging

open access: yesBioconjugate Chemistry, 2014
We report on a chemical platform to generate site-specific, homogeneous, antibody-antibody conjugates by targeting and bridging disulfide bonds. A bispecific antibody construct was produced in good yield through simple reduction and bridging of antibody fragment disulfide bonds, using a readily synthesized bis-dibromomaleimide cross-linker.
Hull, Elizabeth A.   +5 more
openaire   +2 more sources

Purification of anti-BSA-digoxin bispecific antibodies.

open access: yes, 2013
Anti-BSA-digoxin bispecific antibodies were purified from the serum using a series of purification methods. IgG fraction was obtained using 50% saturated ammonium sulfate precipitation, followed by passing through a protein A column.
Jinming Li (128865)   +2 more
core   +1 more source

The emergence of bispecific antibodies as novel cancer therapeutics [PDF]

open access: yes, 2023
Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new
Li, Robert
core  

Revisiting the Carbon Footprint of Single‐Use Technologies in Biomanufacturing: A Bottom‐Up Analysis Reveals a Paradigm Shift

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT The biopharmaceutical industry increasingly relies on single‐use technologies (SUT) for operational flexibility. For a long time, SUT was considered more sustainable than stainless‐steel (SST) systems due to water and energy savings. This study re‐evaluates this paradigm via a detailed bottom‐up analysis of the SUT carbon footprint at the 2000 
Jan Reiners   +4 more
wiley   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia

open access: yesCurrent Issues in Molecular Biology
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells ...
Khalil Saleh   +13 more
doaj   +1 more source

Performance of bispecific Abs and 2 Ab combinations involving bispecifics.

open access: yes, 2018
(A-C) same as Fig 3A–3C, respectively, except combinations of both bispecific Abs and of the type bispecific + conventional Abs are considered. For combinations of 3BNC117-PGT135 bispecific with bnAbs, only V2 glycan bnAbs are considered to ensure non ...
David D. Ho (88133)   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy